Alkermes, Inc. (ALKS) F1Q13 Earnings Conference Call July 26, 2012 08:30 AM ET Executives Richard F. Pops - Chairman and CEO James M. Frates - SVP and CFO Rebecca Peterson - SVP of Corporate Communications Analysts William Tanner - Lazard Capital Markets Anant Padmanabhan - Cowen & Company Thomas Russo - Robert W. Baird & Company, Inc. Karen Jay – J.P. Morgan Securities LLC Steve Byrne - Bank of America/Merrill Lynch Graig Suvannavejh - Jefferies & Company, Inc. Ami Fadia - UBS Investment Bank, Research Division Mario Corso - Caris & Company PresentationOperator
Ladies and gentlemen, thank you for standing by. Welcome to the Alkermes Conference Call to discuss the Company's First Quarter Fiscal 2013 Financial Results. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at Alkermes’ request. At this time, I’d like to introduce your host for today’s call, Ms. Rebecca Peterson, Vice President of Corporate Communications at Alkermes. Please go ahead. Rebecca Peterson Thanks, John. Welcome to the Alkermes PLC conference call to discuss our financial results for the first quarter of the fiscal year 2013, which ended on June 30, 2012. With me today are Richard Pops, our CEO; Shane Cooke, our President; and Jim Frates, our CFO. Before we begin, let me remind you that during the call today, we will make forward-looking statements relating to among other things, our expectations concerning the commercialization of RISPERDAL CONSTA, INVEGA SUSTENNA, AMPYRA/FAMPYRA, BYDUREON and VIVITROL, our future financial expectations and business performance, and our expectations concerning the therapeutic value and clinical development of our products.